Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.

Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.

Abstract

Entities: Chemical Disease Gene Species

Keywords: ALK; ALT; AST; Hepatotoxicity

Source DB: PubMed Journal: Clin Lung Cancer ISSN： 1525-7304 Impact factor: 4.785

× No keyword cloud information.

2 in total

1. [Recommendations from Experts in the Management of Adverse Reactions  to ALK Inhibitors (2021 Version)].

Authors: Ke Wang; Juan Li; Jianguo Sun; Li Li; Xi Zhang; Jianyong Zhang; Min Yu; Xianwei Ye; Ming Zhang; Yu Zhang; Wenxiu Yao; Meijuan Huang
Journal: Zhongguo Fei Ai Za Zhi Date: 2021-10-21

2. Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC.

Authors: Ling Peng; Kui Xiao; Jian Cui; Xiang-Hua Ye; Yong-Chang Zhang; Li Mao; Giovanni Selvaggi; Jennifer Yen; Justin Stebbing
Journal: Onco Targets Ther Date: 2021-05-25 Impact factor: 4.147

2 in total

Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.

1. [Recommendations from Experts in the Management of Adverse Reactions to ALK Inhibitors (2021 Version)].

2. Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC.

1. [Recommendations from Experts in the Management of Adverse Reactions  to ALK Inhibitors (2021 Version)].